骁悉是被广泛用于肾移植急性排斥反应的药物 ,鉴于其具有较好的选择性免疫抑制作用 ,目前已被尝试用于治疗免疫介导的肾小球疾病[1] 。作者采用骁悉治疗了 8例原发性难治性肾病综合征患者 ,除 1例因严重腹泻无法完成治疗 ,3ｄ后退出 ,其余7例均完成治疗 ,并取得了较好的疗效。1 Squad is widely used in acute rejection of renal allograft drugs, in view of its better selective immunosuppressive effect, has been tried for the treatment of immune-mediated glomerular disease [1]. The authors adopted Xiaoxitai treatment of 8 cases of patients with primary refractory nephrotic syndrome, except one case can not be completed due to severe diarrhea, 3d after the withdrawal, the remaining seven cases were completed and achieved good results. 1